ONS ONCC Chemo Renewal
1.Neoadjuvant therapy does not increase survival when compared to
adjuvant therapy. It only changes the timing of treatment and can change
surgical op- tions if the tumor is shrunk enough. If this occurs, the patient
may only require a lumpectomy plus radiation therapy instead of needing a
mastectomy
ANS Main benefit of neoadjuvant chemotherapy (breast cancer patient)
2.A comprehensive geriatric assessment (CGA) is a multidisciplinary
evalua- tion to assess life expectancy and risk of morbidity and mortality in
the older patient. This assessment tool would evaluate and include the
following areas
functional status, socioeconomic issues, psychosocial distress, comorbidi-
ties, cognitive function, nutritional status, polypharmacy, and a medication
review (NCCN Older Adult Oncology Guidelines, version 1.2015).
ANS Due to Mrs. Turner's age and comorbidities, her oncologist
performs a comprehensive geriatric assessment. You know that this
assessment covers all but which of the following
,3.65
ANS The NCCN Older Adult Oncology Guidelines (version 1.2015)
provides in- formation on what is included in a comprehensive geriatric
assessment. Currently, more than 60% of cancers in the United States
occur in people age and
older and as the oncology world ages, nearly half (46%) of cancer
survivors are 70 years of age or older
4.Two of the agents (docetaxel and carboplatin) that Mrs. Turner will receive
are categorized as irritants. Docetaxel can cause a significant reaction if it
extravasates. It can lead to edema, erythema, occasional pain and blister
formation (ONS Chemo/Bio guidelines, 2014). That is the most likely reason
that Mrs. Turner was given a port for her treatments. Some patients will
receive their treatments through a peripheral IV without incident. Just
because they are intravenous agents does not mean that a port is required
and needing a port has nothing to do with her being older in age. Since
none of these agents are vesicants, they likely could have been given safely
via peripheral route but having a port placed is OK as well.
ANS What is your best explanation for why Mrs. Turner was given a port
to receive her chemotherapy?
,5.Irrirtants
ANS can cause inflammation, pain, and burning but
rarely
cause tissue necrosis comparable to a vesicant (unless a large amount
or a very high concentration of the irritant is extravasated).
6.Vesicants
ANS can cause blistering and significant pain and
tissue damage and destruction, leading to tissue death.
7.Non-DNA-binding solutions remain in the local area of the
extravasation, which improves the possibility of drug deactivation.
DNA-binding agents attach to DNA nucleic acids, causing the antagonist
to be ingested cellularly, leading to progressive tissue destruction
ANS A further
, classification of an antineoplastic agent's potential to cause damage is
whether its mechanism of action includes DNA binding.
8.Bendamustinea
Dactinomycin
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Mechlorethamine
Mitomycin
ANS DNA Binding Irritants
9.Amsacrine
Paclitaxel
Vinblastine
Vincristine
Vindesine
Vinorelbine
ANS DNA Nonbinding vessicants
1.Neoadjuvant therapy does not increase survival when compared to
adjuvant therapy. It only changes the timing of treatment and can change
surgical op- tions if the tumor is shrunk enough. If this occurs, the patient
may only require a lumpectomy plus radiation therapy instead of needing a
mastectomy
ANS Main benefit of neoadjuvant chemotherapy (breast cancer patient)
2.A comprehensive geriatric assessment (CGA) is a multidisciplinary
evalua- tion to assess life expectancy and risk of morbidity and mortality in
the older patient. This assessment tool would evaluate and include the
following areas
functional status, socioeconomic issues, psychosocial distress, comorbidi-
ties, cognitive function, nutritional status, polypharmacy, and a medication
review (NCCN Older Adult Oncology Guidelines, version 1.2015).
ANS Due to Mrs. Turner's age and comorbidities, her oncologist
performs a comprehensive geriatric assessment. You know that this
assessment covers all but which of the following
,3.65
ANS The NCCN Older Adult Oncology Guidelines (version 1.2015)
provides in- formation on what is included in a comprehensive geriatric
assessment. Currently, more than 60% of cancers in the United States
occur in people age and
older and as the oncology world ages, nearly half (46%) of cancer
survivors are 70 years of age or older
4.Two of the agents (docetaxel and carboplatin) that Mrs. Turner will receive
are categorized as irritants. Docetaxel can cause a significant reaction if it
extravasates. It can lead to edema, erythema, occasional pain and blister
formation (ONS Chemo/Bio guidelines, 2014). That is the most likely reason
that Mrs. Turner was given a port for her treatments. Some patients will
receive their treatments through a peripheral IV without incident. Just
because they are intravenous agents does not mean that a port is required
and needing a port has nothing to do with her being older in age. Since
none of these agents are vesicants, they likely could have been given safely
via peripheral route but having a port placed is OK as well.
ANS What is your best explanation for why Mrs. Turner was given a port
to receive her chemotherapy?
,5.Irrirtants
ANS can cause inflammation, pain, and burning but
rarely
cause tissue necrosis comparable to a vesicant (unless a large amount
or a very high concentration of the irritant is extravasated).
6.Vesicants
ANS can cause blistering and significant pain and
tissue damage and destruction, leading to tissue death.
7.Non-DNA-binding solutions remain in the local area of the
extravasation, which improves the possibility of drug deactivation.
DNA-binding agents attach to DNA nucleic acids, causing the antagonist
to be ingested cellularly, leading to progressive tissue destruction
ANS A further
, classification of an antineoplastic agent's potential to cause damage is
whether its mechanism of action includes DNA binding.
8.Bendamustinea
Dactinomycin
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Mechlorethamine
Mitomycin
ANS DNA Binding Irritants
9.Amsacrine
Paclitaxel
Vinblastine
Vincristine
Vindesine
Vinorelbine
ANS DNA Nonbinding vessicants
